ReviewDiabetologia2019
Neoepitopes: a new take on beta cell autoimmunity in type 1 diabetes.
Review in Diabetologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Structural Remodeling of TCR-HLA-DQ8 Recognition by a β-Cell Stress-Associated C19S Insulin Neoepitope in Type 1 Diabetes.International journal of molecular sciences · 2026Article
- T cell and autoantibody recognition of nucleus-associated islet autoantigens in individuals with type 1 diabetes.Diabetologia · 2025Article
- Current and Emerging Assays for Measuring Human T-Cell Responses Against Beta-Cell Antigens in Type 1 Diabetes.Biomolecules · 2025Review
- Exploring new frontiers in type 1 diabetes through advanced mass-spectrometry-based molecular measurements.Trends in molecular medicine · 2024Review
- Proinsulin C-peptide is a major source of HLA-DQ8 restricted hybrid insulin peptides recognized by human islet-infiltrating CD4PNAS nexus · 2024Article
- Gut virome and diabetes: discovering links, exploring therapies.Archives of microbiology · 2024Review
- Physical Activity as a Modern Intervention in the Fight against Obesity-Related Inflammation in Type 2 Diabetes Mellitus and Gestational Diabetes.Antioxidants (Basel, Switzerland) · 2023Review
- Glutamine deamidation does not increase the immunogenicity of C-peptide in people with type 1 diabetes.Journal of translational autoimmunity · 2023Article
- A gut microbial peptide and molecular mimicry in the pathogenesis of type 1 diabetes.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- The β Cell in Diabetes: Integrating Biomarkers With Functional Measures.Endocrine reviews · 2021Review
- T cell receptor recognition of hybrid insulin peptides bound to HLA-DQ8.Nature communications · 2021Article
- Expression of immunoreactive inducible nitric oxide synthase in pancreatic islet cells from newly diagnosed and long-term type 1 diabetic donors is heterogeneous and not disease-associated.Cell and tissue research · 2021Article
- Article
- β-cell self-destruction and extremely complicated and still unknown etiopathogenesis of type 1 diabetes.Pediatric endocrinology, diabetes, and metabolism · 2021Review
- The Role of Gut Microbiota and Environmental Factors in Type 1 Diabetes Pathogenesis.Frontiers in endocrinology · 2020Review
- Modulatory Mechanisms of the NLRP3 Inflammasomes in Diabetes.Biomolecules · 2019Review
- HIPs and HIP-reactive T cells.Clinical and experimental immunology · 2019Review
- Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?Frontiers in immunology · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes is an autoimmune disease caused by T cell-mediated destruction of pancreatic insulin-producing beta cells. The epitopes recognised by pathogenic T cells in human type 1 diabetes are poorly defined; however, a growing body of evidence suggests that T cell responses against neoepitopes contribute to beta cell destruction in type 1 diabetes. Neoepitopes are formed when self-proteins undergo post-translational modification to create a new epitope that is recognised by T- or B cells. Here we review the role of human T cell responses against neoepitopes in the immune pathogenesis of type 1 diabetes. Specifically, we review the different approaches to identifying neoepitopes relevant to human type 1 diabetes and outline several advances in this field that have occurred over the past few years. We also discuss the application of neoepitopes to the development of antigen-specific therapies for type 1 diabetes and the unresolved challenges that need to be overcome before the full repertoire of neoepitopes recognised by pathogenic human T cells in type 1 diabetes can be determined. This information may then be used to develop antigen-specific therapies for type 1 diabetes and assays to monitor changes in pathogenic, beta cell-specific T cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.